ReviewSurgery today2017
History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.
Review in Surgery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Long noncoding RNA MALAT1 as a candidate serological biomarker for the diagnosis of non-small cell lung cancer: A meta-analysis.Thoracic cancer · 2020Pooled it
- Pooled it
- Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial.Cancer science · 2020Trial
- Detection of a group of classic serum tumor markers (CSTMs) aids in the differential diagnosis and disease assessment of upper tract urothelial carcinoma (UTUC).Translational andrology and urology · 2026Article
- Dissecting non-small cell lung cancer (NSCLC) with blood proteomics-from surgical to immunotherapeutic responses.NPJ precision oncology · 2026Article
- Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.Clinical and translational science · 2026Review
- Unique Clinical Features of Imaging-Stage I Peripheral Lung Squamous Cell Carcinoma: A Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers.Biochemia medica · 2025Observational
- MiRNA sequencing of platelet and exosome revealed platelet miR-199b-3p as a potential biomarker in lung adenocarcinoma.Frontiers in immunology · 2025Article
- Differential diagnosis of benign and malignant vertebral compression fractures based on CT radiomics model.Frontiers in oncology · 2025Article
- Serum tumor markers: potential indicators for occult lymph node metastasis in clinical TRespiratory research · 2024Article
- Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG).EClinicalMedicine · 2024Article
- Analysis of influencing factors of serum SCCA elevation in 309 CAP patients with normal CEA,NSE and CYFRA21-1.Frontiers in oncology · 2024Article
- A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.CPT: pharmacometrics & systems pharmacology · 2023Article
- Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.Targeted oncology · 2023Observational
- Artificial neural network-based diagnostic models for lung cancer combining conventional indicators with tumor markers.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer.Cancer medicine · 2023Article
- The value of serum TRAP1 in diagnosing small cell lung cancer and tumor immunity.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Early detection of lung cancer in a real-world cohortFrontiers in oncology · 2023Article
- Non-Targeted Serum Lipidomics Analysis and Potential Biomarkers of Laryngeal Cancer Based on UHPLC-QTOF-MS.Metabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum biomarkers provide valuable information about the diagnosis and prognosis of a wide variety of malignant tumors. Despite the identification of several useful serum biomarkers in lung cancer, consensus on their utility has not yet been reached. Furthermore, guidelines and standard protocols to implement their use for patients with lung cancer are lacking, despite the accumulation of much data on the efficacy of several serum biomarkers over recent decades. In this review, we discuss the molecular features, functions, and clinical relevance of the conventional serum biomarkers for lung cancer, including carcinoembryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA 21-1), tissue polypeptide antigen (TPA), carbohydrate antigen 19-9 (CA19-9), sialyl Lewis
Indexed as
Identifiers
28229299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.